Comparative quantification of chemotherapy-induced nausea and emesis between the common terminology criteria for adverse events and the multinational association of supportive care in cancer antiemesis tool

Mayako Uchida, Tsutomu Nakamura, Takahiro Shima, Goichi Yoshimoto, Koji Kato, Keiko Hosohata, Toshihiro Miyamoto, Koichi Akashi

Research output: Contribution to journalArticle

Abstract

Chemotherapy-induced nausea and vomiting (CINV) are generally evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE). The Multinational Association for Supportive Care in Cancer (MASCC) developed the MASCC Antiemesis Tool (MAT) to facilitate recognition for CINV between patients and oncology specialists. In the present study, MAT and CTCAE were comparatively assessed in Japanese patients with hematological malignancies. A total of 61 patients were eligible for this study. The CTCAE data were collected from an electronic medical record system. The patients were asked to complete the Japanese version of MAT in the hospital, on the first and fourth days after the start of chemotherapy. The percentages of patients in whom nausea was completely controlled, with severity scores of zero, ranged from 70.5 to 82.0% for CTCAE and from 59.0 to 75.4% for MAT, during the first five days after the chemotherapy. The percentages of patients who had no vomiting ranged from 93.4 to 96.7% for CTCAE and from 90.2 to 98.4% for MAT. During the observation periods, the day-to-day response profiles of patients who received antiemetic treatment were comparable between CTCAE and MAT cohorts, and these two assessment tools showed good, positive correlations for nausea severity scores. The present study shows that the MAT is a useful tool for assessing the severity of CINV in patients with hematological malignancy, is comparable to CTCAE, and facilitates the identification of poor cancer care conditions by medical staff.

Original languageEnglish
Pages (from-to)1667-1671
Number of pages5
JournalBiological and Pharmaceutical Bulletin
Volume41
Issue number11
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Terminology
Nausea
Vomiting
Drug Therapy
Neoplasms
Hematologic Neoplasms
Antiemetics
Electronic Health Records
Medical Staff
Observation

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmaceutical Science

Cite this

@article{3544d68bd7304d1a9feeb6edba217a3d,
title = "Comparative quantification of chemotherapy-induced nausea and emesis between the common terminology criteria for adverse events and the multinational association of supportive care in cancer antiemesis tool",
abstract = "Chemotherapy-induced nausea and vomiting (CINV) are generally evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE). The Multinational Association for Supportive Care in Cancer (MASCC) developed the MASCC Antiemesis Tool (MAT) to facilitate recognition for CINV between patients and oncology specialists. In the present study, MAT and CTCAE were comparatively assessed in Japanese patients with hematological malignancies. A total of 61 patients were eligible for this study. The CTCAE data were collected from an electronic medical record system. The patients were asked to complete the Japanese version of MAT in the hospital, on the first and fourth days after the start of chemotherapy. The percentages of patients in whom nausea was completely controlled, with severity scores of zero, ranged from 70.5 to 82.0{\%} for CTCAE and from 59.0 to 75.4{\%} for MAT, during the first five days after the chemotherapy. The percentages of patients who had no vomiting ranged from 93.4 to 96.7{\%} for CTCAE and from 90.2 to 98.4{\%} for MAT. During the observation periods, the day-to-day response profiles of patients who received antiemetic treatment were comparable between CTCAE and MAT cohorts, and these two assessment tools showed good, positive correlations for nausea severity scores. The present study shows that the MAT is a useful tool for assessing the severity of CINV in patients with hematological malignancy, is comparable to CTCAE, and facilitates the identification of poor cancer care conditions by medical staff.",
author = "Mayako Uchida and Tsutomu Nakamura and Takahiro Shima and Goichi Yoshimoto and Koji Kato and Keiko Hosohata and Toshihiro Miyamoto and Koichi Akashi",
year = "2018",
month = "1",
day = "1",
doi = "10.1248/bpb.b18-00336",
language = "English",
volume = "41",
pages = "1667--1671",
journal = "Biological and Pharmaceutical Bulletin",
issn = "0918-6158",
publisher = "Pharmaceutical Society of Japan",
number = "11",

}

TY - JOUR

T1 - Comparative quantification of chemotherapy-induced nausea and emesis between the common terminology criteria for adverse events and the multinational association of supportive care in cancer antiemesis tool

AU - Uchida, Mayako

AU - Nakamura, Tsutomu

AU - Shima, Takahiro

AU - Yoshimoto, Goichi

AU - Kato, Koji

AU - Hosohata, Keiko

AU - Miyamoto, Toshihiro

AU - Akashi, Koichi

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Chemotherapy-induced nausea and vomiting (CINV) are generally evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE). The Multinational Association for Supportive Care in Cancer (MASCC) developed the MASCC Antiemesis Tool (MAT) to facilitate recognition for CINV between patients and oncology specialists. In the present study, MAT and CTCAE were comparatively assessed in Japanese patients with hematological malignancies. A total of 61 patients were eligible for this study. The CTCAE data were collected from an electronic medical record system. The patients were asked to complete the Japanese version of MAT in the hospital, on the first and fourth days after the start of chemotherapy. The percentages of patients in whom nausea was completely controlled, with severity scores of zero, ranged from 70.5 to 82.0% for CTCAE and from 59.0 to 75.4% for MAT, during the first five days after the chemotherapy. The percentages of patients who had no vomiting ranged from 93.4 to 96.7% for CTCAE and from 90.2 to 98.4% for MAT. During the observation periods, the day-to-day response profiles of patients who received antiemetic treatment were comparable between CTCAE and MAT cohorts, and these two assessment tools showed good, positive correlations for nausea severity scores. The present study shows that the MAT is a useful tool for assessing the severity of CINV in patients with hematological malignancy, is comparable to CTCAE, and facilitates the identification of poor cancer care conditions by medical staff.

AB - Chemotherapy-induced nausea and vomiting (CINV) are generally evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE). The Multinational Association for Supportive Care in Cancer (MASCC) developed the MASCC Antiemesis Tool (MAT) to facilitate recognition for CINV between patients and oncology specialists. In the present study, MAT and CTCAE were comparatively assessed in Japanese patients with hematological malignancies. A total of 61 patients were eligible for this study. The CTCAE data were collected from an electronic medical record system. The patients were asked to complete the Japanese version of MAT in the hospital, on the first and fourth days after the start of chemotherapy. The percentages of patients in whom nausea was completely controlled, with severity scores of zero, ranged from 70.5 to 82.0% for CTCAE and from 59.0 to 75.4% for MAT, during the first five days after the chemotherapy. The percentages of patients who had no vomiting ranged from 93.4 to 96.7% for CTCAE and from 90.2 to 98.4% for MAT. During the observation periods, the day-to-day response profiles of patients who received antiemetic treatment were comparable between CTCAE and MAT cohorts, and these two assessment tools showed good, positive correlations for nausea severity scores. The present study shows that the MAT is a useful tool for assessing the severity of CINV in patients with hematological malignancy, is comparable to CTCAE, and facilitates the identification of poor cancer care conditions by medical staff.

UR - http://www.scopus.com/inward/record.url?scp=85055808001&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055808001&partnerID=8YFLogxK

U2 - 10.1248/bpb.b18-00336

DO - 10.1248/bpb.b18-00336

M3 - Article

C2 - 30381666

AN - SCOPUS:85055808001

VL - 41

SP - 1667

EP - 1671

JO - Biological and Pharmaceutical Bulletin

JF - Biological and Pharmaceutical Bulletin

SN - 0918-6158

IS - 11

ER -